Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe 10:54:10 2024-04-19 EDT 5-day change 1st Jan Change
85.26 CHF +0.88% Intraday chart for Novartis AG -1.17% +0.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US FDA mandates label updates on CAR-T cancer therapies RE
NOVARTIS AG : UBS reiterates its Buy rating ZD
TotalEnergies: shareholders want to separate powers CF
NOVARTIS AG : Deutsche Bank maintains a Buy rating ZD
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years MT
Novartis: positive efficacy data in MS CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis DJ
Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB?s Bimzelx Poised to Further Disrupt the Market CI
Novartis reports positive interim results for Fabhalta CF
Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients MT
Novartis Gets Priority Review for Kidney Disease Treatment DJ
New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) DJ
Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta CI
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug MT
Health Care Slips on Risk Bias -- Health Care Roundup DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares DJ
Novartis: licensing agreement in prostate cancer CF
Novartis: MorphoSys Board recommends tender offer CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins MT
Morphosys management bodies recommend acceptance of Novartis takeover bid DP
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion RE
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
92.75 USD
Average target price
106.3 USD
Spread / Average Target
+14.59%
Consensus
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says